Antiplatelet agents in cardiology

A report on aspirin, clopidogrel, prasugrel, and ticagrelor

Paul P Dobesh, Sara Varnado, Meagan Doyle

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Antiplatelet drugs are the cornerstone of therapy in many cardiovascular conditions. With the current success and increased use of transcatheter aortic valve implantation (TAVI), the use of antiplatelet therapy is considered part of the medical therapy for these patients. Clinicians caring for these patients need to have a thorough understanding of the pharmacology, pharmacokinetics, pharmacodynamic, and clinical efficacy and safety of commonly used antiplatelet therapy. While aspirin therapy is widely used, dual antiplatelet therapy with clopidogrel has become part of standard of care. Despite the extensive experience with clopidogrel, there are limitations such as drug interactions, metabolism genetic polymorphisms, and variability in the antiplatelet response. More predictable and more potent antiplatelet agents, prasugrel and ticagrelor, have demonstrated superior reductions in ischemic endpoints as part of dual antiplatelet therapy compared to clopidogrel, but at the cost of more major bleeding in patients with an acute coronary syndrome. Significant research needs to be conducted in the setting of TAVI to help define the optimal antiplatelet regimen.

Original languageEnglish (US)
Pages (from-to)1918-1932
Number of pages15
JournalCurrent Pharmaceutical Design
Volume22
Issue number13
StatePublished - Apr 1 2016

Fingerprint

clopidogrel
Platelet Aggregation Inhibitors
Cardiology
Aspirin
Therapeutics
Genetic Polymorphisms
Standard of Care
Acute Coronary Syndrome
Drug Interactions
Prasugrel Hydrochloride
Ticagrelor
Pharmacokinetics
Pharmacology
Hemorrhage

Keywords

  • Antiplatelet agents
  • Aspirin
  • Clopidogrel
  • P2Y inhibitors
  • Prasugrel
  • Ticagrelor

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Antiplatelet agents in cardiology : A report on aspirin, clopidogrel, prasugrel, and ticagrelor. / Dobesh, Paul P; Varnado, Sara; Doyle, Meagan.

In: Current Pharmaceutical Design, Vol. 22, No. 13, 01.04.2016, p. 1918-1932.

Research output: Contribution to journalArticle

@article{96873633d79545208a8e5d437e734a7f,
title = "Antiplatelet agents in cardiology: A report on aspirin, clopidogrel, prasugrel, and ticagrelor",
abstract = "Antiplatelet drugs are the cornerstone of therapy in many cardiovascular conditions. With the current success and increased use of transcatheter aortic valve implantation (TAVI), the use of antiplatelet therapy is considered part of the medical therapy for these patients. Clinicians caring for these patients need to have a thorough understanding of the pharmacology, pharmacokinetics, pharmacodynamic, and clinical efficacy and safety of commonly used antiplatelet therapy. While aspirin therapy is widely used, dual antiplatelet therapy with clopidogrel has become part of standard of care. Despite the extensive experience with clopidogrel, there are limitations such as drug interactions, metabolism genetic polymorphisms, and variability in the antiplatelet response. More predictable and more potent antiplatelet agents, prasugrel and ticagrelor, have demonstrated superior reductions in ischemic endpoints as part of dual antiplatelet therapy compared to clopidogrel, but at the cost of more major bleeding in patients with an acute coronary syndrome. Significant research needs to be conducted in the setting of TAVI to help define the optimal antiplatelet regimen.",
keywords = "Antiplatelet agents, Aspirin, Clopidogrel, P2Y inhibitors, Prasugrel, Ticagrelor",
author = "Dobesh, {Paul P} and Sara Varnado and Meagan Doyle",
year = "2016",
month = "4",
day = "1",
language = "English (US)",
volume = "22",
pages = "1918--1932",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "13",

}

TY - JOUR

T1 - Antiplatelet agents in cardiology

T2 - A report on aspirin, clopidogrel, prasugrel, and ticagrelor

AU - Dobesh, Paul P

AU - Varnado, Sara

AU - Doyle, Meagan

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Antiplatelet drugs are the cornerstone of therapy in many cardiovascular conditions. With the current success and increased use of transcatheter aortic valve implantation (TAVI), the use of antiplatelet therapy is considered part of the medical therapy for these patients. Clinicians caring for these patients need to have a thorough understanding of the pharmacology, pharmacokinetics, pharmacodynamic, and clinical efficacy and safety of commonly used antiplatelet therapy. While aspirin therapy is widely used, dual antiplatelet therapy with clopidogrel has become part of standard of care. Despite the extensive experience with clopidogrel, there are limitations such as drug interactions, metabolism genetic polymorphisms, and variability in the antiplatelet response. More predictable and more potent antiplatelet agents, prasugrel and ticagrelor, have demonstrated superior reductions in ischemic endpoints as part of dual antiplatelet therapy compared to clopidogrel, but at the cost of more major bleeding in patients with an acute coronary syndrome. Significant research needs to be conducted in the setting of TAVI to help define the optimal antiplatelet regimen.

AB - Antiplatelet drugs are the cornerstone of therapy in many cardiovascular conditions. With the current success and increased use of transcatheter aortic valve implantation (TAVI), the use of antiplatelet therapy is considered part of the medical therapy for these patients. Clinicians caring for these patients need to have a thorough understanding of the pharmacology, pharmacokinetics, pharmacodynamic, and clinical efficacy and safety of commonly used antiplatelet therapy. While aspirin therapy is widely used, dual antiplatelet therapy with clopidogrel has become part of standard of care. Despite the extensive experience with clopidogrel, there are limitations such as drug interactions, metabolism genetic polymorphisms, and variability in the antiplatelet response. More predictable and more potent antiplatelet agents, prasugrel and ticagrelor, have demonstrated superior reductions in ischemic endpoints as part of dual antiplatelet therapy compared to clopidogrel, but at the cost of more major bleeding in patients with an acute coronary syndrome. Significant research needs to be conducted in the setting of TAVI to help define the optimal antiplatelet regimen.

KW - Antiplatelet agents

KW - Aspirin

KW - Clopidogrel

KW - P2Y inhibitors

KW - Prasugrel

KW - Ticagrelor

UR - http://www.scopus.com/inward/record.url?scp=84964303662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964303662&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 1918

EP - 1932

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 13

ER -